SCOTTSDALE, Ariz., May 3, 2012 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the Company expects to report 2012 first quarter financial results after the market closes on Tuesday, May 8, 2012. Medicis will host a conference call at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) to review the March 31, 2012, first quarter financial results, as well as provide an update on other business matters of the Company. A live webcast will be available at http://www.Medicis.com/company/index.asp. The webcast will be archived on the Company's website for 10 business days following the live call.
Callers should dial in approximately 10 minutes prior to the start of the call. No reservation is necessary to participate on the call. The phone number to join the conference call is +1 (877) 233-0981 (U.S. and Canada) or +1 (706) 679-5708 (international and local). The access code for the live call is 77875357. For investors unable to participate on the live call, a replay will be available soon after the live call. The phone number to access the replay is +1 (800) 585-8367 (U.S. and Canada) or +1 (404) 537-3406 (international and local). The access code for the replay is 77875357. The replay will be available for 10 business days following the live call.
Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic and aesthetic categories. The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.
For more information about Medicis or the Company's products, please visit the Company's website at www.Medicis.com. Printed copies of the Company's complete audited financial statements are available free of charge upon request.
Kara Stancell (media)
Sean Andrews (investors)